{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:19:03Z","timestamp":1763986743510,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clcc.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:41:34Z","timestamp":1473381694000},"page":"e73-e88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study"],"prefix":"10.1016","volume":"16","author":[{"given":"Ann-Lii","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Cornelio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ik Joo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Hai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Kou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Huei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Zaatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongzhen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehal","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vichien","family":"Srimuninnimit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh Chandra","family":"Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Taek","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Yong","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charity","family":"Gorospe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwei-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaphop","family":"Sirachainan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Wook","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Beier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudipto","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2016.08.005_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ejca.2015.04.007","article-title":"FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"51","author":"Bokemeyer","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2016.08.005_bib3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.08.005_bib4","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"year":"2013","series-title":"Erbitux [PI] Erbitux (Cetuximab) for Injection [Package Insert]","key":"10.1016\/j.clcc.2016.08.005_bib6"},{"key":"10.1016\/j.clcc.2016.08.005_bib7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/annonc\/mdt116","article-title":"FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study","volume":"24","author":"Brodowicz","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1186\/1471-2407-14-865","article-title":"Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)","volume":"14","author":"Fernandez-Plana","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2016.08.005_bib9","first-page":"170","article-title":"Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 study by the Nordic Colorectal Cancer Biomodulation Group","volume":"14","author":"Pfeiffer","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2016.08.005_bib10","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdp549","article-title":"Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic\/pharmacodynamic phase I dose-escalation study","volume":"21","author":"Tabernero","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/era.13.37","article-title":"Current opinion on optimal treatment for colorectal cancer","volume":"13","author":"Price","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clcc.2016.08.005_bib12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib13","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3748\/wjg.v16.i25.3133","article-title":"Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial","volume":"16","author":"Ocvirk","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2016.08.005_bib14","first-page":"91","article-title":"FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: updated analysis of the CECOG\/CORE 1.2.002 study","volume":"14","author":"Kaczirek","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2016.08.005_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clcc.2016.08.005_bib16","article-title":"Lenz HJ, Niedzwiecki D, Innocenti F. CALGB\/SWOG 80405: Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in untreated metastatic adenocarcinoma of the colon or rectum","volume":"25","author":"Lenz","year":"2014","journal-title":"Ann Oncol"},{"issue":"5 suppl","key":"10.1016\/j.clcc.2016.08.005_bib17","volume":"32","author":"Venook","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/modpathol.2012.150","article-title":"Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer","volume":"26","author":"Voutsina","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clcc.2016.08.005_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.critrevonc.2012.05.001","article-title":"Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations","volume":"85","author":"Custodio","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 3","key":"10.1016\/j.clcc.2016.08.005_bib20","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.08.005_bib22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.cad.0000217425.44584.9f","article-title":"Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer","volume":"17","author":"Hebbar","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clcc.2016.08.005_bib23","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1200\/JCO.2012.42.8532","article-title":"Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab","volume":"31","author":"Piessevaux","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clcc.2016.08.005_bib24","article-title":"Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population","volume":"25","author":"Stintzing","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clcc.2016.08.005_bib25","article-title":"Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC","volume":"31","author":"Mansmann","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2016.08.005_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","article-title":"Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial","volume":"15","author":"Wasan","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816301529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816301529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:05:09Z","timestamp":1761519909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002816301529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1533002816301529"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2016.08.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}